SKL 15508

Drug Profile

SKL 15508

Alternative Names: SKL A4R; SKL15508

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK biopharmaceuticals
  • Class Nootropics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cognition disorders
  • No development reported Mental disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mental-disorders in South Korea (PO)
  • 01 Jun 2015 SK Biopharmaceuticals completes a phase I/II trial in for Cognition disorders iin schizophrenia in USA (NCT02205099)
  • 17 Apr 2013 Preclinical trials in Mental disorders in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top